Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Abbreviations: PB, phosphate binder; SD, standard deviation; SFOH, sucroferric oxyhydroxideCKD-MBD parameters and phosphate binder pill burden at baseline and during sucroferric oxyhydroxide follow-up (Q1 to Q4) in the overall study cohort (N = 1096)ParameterBaseline(N = 1089)Q1(N = 968)Q2(N = 738)Q3(N = 536)Q4(N = 378)Serum phosphate, mmol/L1.88 ± 0.361.77 ± 0.41***1.70 ± 0.40***1.70 ± 0.42***1.69 ± 0.42***Serum PTH, pmol/L47.5 ± 46.748.8 ± 46.048.4 ± 47.250.6 ± 52.752.1 ± 51.8Serum calcium, mmol/L2.24 ± 0.162.23 ± 0.17*2.24 ± 0.172.24 ± 0.172.24 ± 0.16Total phosphate binder pill consumption, pills/day6.3 ± 9.05.1 ± 7.65.0 ± 5.45.3 ± 5.65.2 ± 5.5SFOH pill consumption, pills/dayN/A2.3 ± 1.42.5 ± 1.52.6 ± 1.52.6 ± 1.5SFOH dose, mg/dayN/A1172 ± 7181236 ± 7731285 ± 7701308 ± 765Number of patients receiving cinacalcet, n (%)355 (32.6)357 (36.9)267 (36.2)200 (37.3)148 (39.2)Number of patients receiving vitamin D analogs, n (%)426 (39.1)372 (38.4)293 (39.7)223 (41.6)158 (41.8)*p < 0.05; ***p < 0.0001 (vs baseline)All values are mean ± SD unless otherwise specifiedAbbreviations: CKD-MBD chronic kidney disease-bone and mineral disorder, PTH parathyroid hormone, N/A not applicable, SD standard deviation, SFOH sucroferric oxyhydroxideProportion of patients achieving target serum phosphate (≤ 1.78 mmol/L) by country. *p < 0.05; **p < 0.001; ***p < 0.0001 (vs baseline); aThe serum phosphate data for Russia for Q3 and Q4 are not shown because the number of patients with follow-up data available was too low for meaningful analysis (Q3, n = 7; Q4, n = 0)
Source: Changes in serum phosphate. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Patients were defined as ‘phosphate binder-pretreated’ or ‘phosphate binder-naïve’ according to whether they received phosphate binder therapy or not during the 3-month baseline period.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis
Study design awaiting verification · BMC Nephrology · 2020
Original publication title
The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis
© The Author(s) 2020
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
The iron-based phosphate binder (PB), sucroferric oxyhydroxide (SFOH), demonstrated its effectiveness for lowering serum phosphate levels, with low daily pill burden, in clinical trials of dialysis patients with hyperphosphatemia. This retrospective database analysis evaluated the real-world effectiveness of SFOH for controlling serum phosphate in European hemodialysis patients.
Source: BackgroundAbstract: What methods does the paper describe?
De-identified patient data were extracted from a clinical database (EuCliD®) for adult hemodialysis patients from France, Italy, Portugal, Russia and Spain who were newly prescribed SFOH for up to 1 year as part of routine clinical care. Serum phosphate and pill burden were compared between baseline (3-month period before starting SFOH) and four consecutive quarterly periods of SFOH therapy (Q1−Q4; 12 months) in the overall cohort and three subgroups: PB-naïve patients treated with SFOH monotherapy (mSFOH), and PB-pretreated patients who were either switched to SFOH monotherapy (PB → mSFOH), or received SFOH in addition to another PB (PB + SFOH).
Source: MethodsAbstract: Results
1096 hemodialysis patients (mean age: 60.6 years; 65.8% male) were analyzed, including 796, 188 and 53 patients in, respectively, the PB + SFOH, mSFOH, and PB → mSFOH groups. In the overall cohort, serum phosphate decreased significantly from 1.88 mmol/L at baseline to 1.77 to 1.69 mmol/L during Q1: Q4, and the proportion of patients achieving serum phosphate ≤1.78 mmol/L increased from 41.3% at baseline to 56.2 to 62.7% during SFOH treatment. Mean PB pill burden decreased from 6.3 pills/day at baseline to 5.0 to 5.3 pills/day during Q1: Q4.
The subgroup analysis found the proportion of patients achieving serum phosphate ≤1.78 mmol/L increased significantly from baseline during SFOH treatment in the PB + SFOH group (from 38.1% up to 60.9% [Q2]) and the mSFOH group (from 49.5% up to 75.2% [Q2]), but there were no significant changes in the PB → mSFOH group. For the PB + SFOH group, serum phosphate reductions were achieved with a similar number of PB pills prescribed at baseline prior to SFOH treatment (6.5 vs 6.2 pills/day at Q4).
SFOH daily pill burden was low across all 3 subgroups (2.1 to 2.8 pills/day).
Source: ResultsAbstract: Conclusion
In this real-world study of European hemodialysis patients, prescription of SFOH as monotherapy to PB-naïve patients, or in addition to existing PB therapy, was associated with significant improvements in serum phosphate control and a low daily pill burden.
Source: ConclusionAuthors’ abstract
Background
The iron-based phosphate binder (PB), sucroferric oxyhydroxide (SFOH), demonstrated its effectiveness for lowering serum phosphate levels, with low daily pill burden, in clinical trials of dialysis patients with hyperphosphatemia. This retrospective database analysis evaluated the real-world effectiveness of SFOH for controlling serum phosphate in European hemodialysis patients.
Methods
De-identified patient data were extracted from a clinical database (EuCliD®) for adult hemodialysis patients from France, Italy, Portugal, Russia and Spain who were newly prescribed SFOH for up to 1 year as part of routine clinical care. Serum phosphate and pill burden were compared between baseline (3-month period before starting SFOH) and four consecutive quarterly periods of SFOH therapy (Q1−Q4; 12 months) in the overall cohort and three subgroups: PB-naïve patients treated with SFOH monotherapy (mSFOH), and PB-pretreated patients who were either switched to SFOH monotherapy (PB → mSFOH), or received SFOH in addition to another PB (PB + SFOH).
Results
1096 hemodialysis patients (mean age: 60.6 years; 65.8% male) were analyzed, including 796, 188 and 53 patients in, respectively, the PB + SFOH, mSFOH, and PB → mSFOH groups. In the overall cohort, serum phosphate decreased significantly from 1.88 mmol/L at baseline to 1.77 to 1.69 mmol/L during Q1: Q4, and the proportion of patients achieving serum phosphate ≤1.78 mmol/L increased from 41.3% at baseline to 56.2 to 62.7% during SFOH treatment. Mean PB pill burden decreased from 6.3 pills/day at baseline to 5.0 to 5.3 pills/day during Q1: Q4.
The subgroup analysis found the proportion of patients achieving serum phosphate ≤1.78 mmol/L increased significantly from baseline during SFOH treatment in the PB + SFOH group (from 38.1% up to 60.9% [Q2]) and the mSFOH group (from 49.5% up to 75.2% [Q2]), but there were no significant changes in the PB → mSFOH group. For the PB + SFOH group, serum phosphate reductions were achieved with a similar number of PB pills prescribed at baseline prior to SFOH treatment (6.5 vs 6.2 pills/day at Q4).
SFOH daily pill burden was low across all 3 subgroups (2.1 to 2.8 pills/day).
Conclusion
In this real-world study of European hemodialysis patients, prescription of SFOH as monotherapy to PB-naïve patients, or in addition to existing PB therapy, was associated with significant improvements in serum phosphate control and a low daily pill burden.
Publication and source details
Original title: The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis
Rosa Ramos; Charles Chazot; Anibal Ferreira; Attilio Di Benedetto; Konstantin Gurevich; Astrid Feuersenger; Melanie Wolf; Hans-Jürgen Arens; Sebastian Walpen; Stefano Stuard
BMC Nephrology · 2020
© The Author(s) 2020https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.http://dx.doi.org/10.13039/501100006484Vifor PharmaN/ARepository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T13:53:27.890360+00:00
DOI: 10.1186/s12882-020-02188-8 · PMC7720479